Latest Feature Articles
Damage control: How will pharma manage the health economic impacts of Brexit?
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | HEOR, brexit, health economics and outcomes research, pharmaWhen it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the …
“No deal” Brexit and life sciences: What happens?
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | EU, Europe, UK, brexit, no deal, no-deal, pharmaPrime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …
Medical cannabis: Growth by leaps and bounds
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Canada, Canopy Growth, medical cannabis, pharmaThis article follows parts one and two of our trio of in-depth pieces focusing on the growing medical cannabis phenomenon. …
Medical cannabis: Riding the wave
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Kanabo research, medical cannabis, pharmaFollowing on from our previous piece from Mewburn Ellis on the history of social attitudes towards cannabis, Israel-based Kanabo Research …
Medical cannabis: On to greener pastures?
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | medical cannabis, medicinal cannabis, pharmaIn the first of three articles on the topic, Callum McGuinn, Associate and European Patent Attorney at Mewburn Ellis, explores …
Three focus areas to accelerate breakthrough drugs to market
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | veevaThe number of clinical trials taking place each year continues to rise. In fact, in 2018, the FDA approved a …
The Lung Ambition Alliance: Stronger together
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cancer, Lung Ambition Alliance, lung cancer, pharmaFollowing our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …
Breaking through limits in lung cancer: Introducing the Lung Ambition Alliance
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cancer, Lung Ambition Alliance, feature, lung cancer, pharmaLung cancer kills more patients than any other variety of cancer, accounting for around a fifth of all cancer-related deaths …
The world needs a better plan for cancer survival by 2030
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cancer, Roche, UN General Assembly, United Nations, feature, opinion, pharmaBeginning on 24 September, the UN will convene in New York for its annual General Assermbly. Dr Christian Rommel, Roche´s …
Living with acute myeloid leukaemia
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | acute myeloid leukaemia, feature, patient experience, pharmaSteve Rothberg was blindsided by an AML diagnosis that progressed rapidly with little warning. Ten years later, he discusses his …
Breaking through limits in lung cancer: Introducing The Lung Ambition Alliance
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Cancer, Lung Ambition Alliance, lung cancer, oncology, pharmaPatrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, at AstraZeneca, discusses his company’s role in the …
Trump’s FDA: Is the US regulator being steered by the President?
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | FDA, Trump, US, drug safety, pharmaFDA activity has fallen under Donald Trump, with the number of warning letters issued by the regulator dropping by a …
Key legal considerations in accelerating pharma using artificial intelligence
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AI, artificial intelligence, pharmaCharlotte Walker-Osborn, Partner and International Technology Sector Head and Nabil Asaad, Senior Associate, Intellectual Property Law Group – both from …
Working Life: Linda Armstrong, Global Head, Respiratory Development Unit at Novartis
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Novartis, Working Life, feature, pharmaLinda Armstrong, Global Head, Respiratory Development Unit at Novartis.
Finding the needle in the haystack of rare disease
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AI, Genomenon, Rare Genomics Institute, pharma, rare diseaseThrough the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory …
